Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Sang Hoon | - |
dc.contributor.author | Park, Choong Kee | - |
dc.contributor.author | Lee, Jin Woo | - |
dc.contributor.author | Kim, Young Seok | - |
dc.contributor.author | Jeong, Sook-Hyang | - |
dc.contributor.author | Kim, Yun Soo | - |
dc.contributor.author | Kim, Ju Hyun | - |
dc.contributor.author | Hwang, Seong Gyu | - |
dc.contributor.author | Rim, Kyu Sung | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Cheong, Jae Youn | - |
dc.contributor.author | Cho, Sung Won | - |
dc.contributor.author | Lee, June Sung | - |
dc.contributor.author | Park, Young Min | - |
dc.contributor.author | Jang, Jeong Won | - |
dc.contributor.author | Lee, Chun Kyon | - |
dc.contributor.author | Shon, Joo Hyun | - |
dc.contributor.author | Yang, Jin Mo | - |
dc.contributor.author | Ju, Young Soo | - |
dc.date.accessioned | 2021-09-06T23:35:49Z | - |
dc.date.available | 2021-09-06T23:35:49Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2012-01 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/109229 | - |
dc.description.abstract | Background/Aims: We aimed to evaluate the efficacy and safety of peginterferon plus ribavirin for chronic hepatitis C (CHC) patients under real life setting in Korea. Methods: We retrospectively analyzed the medical records of 758 CHC patients treated with peginterferon plus ribavirin between 2000 and 2008 from 14 university hospitals in the Gyeonggi-Incheon area in Korea. Results: Hepatitis C virus (HCV) genotype 1 was detected in 61.2% of patients, while genotype 2 was detected in 35.5%. Baseline HCV RNA level was >= 6x10(5) IU/mL in 51.6% of patients. The sustained virological response (SVR) rate was 59.6% regardless of genotype; 53.6% in genotype 1 and 71.4% in genotype 2/3. On multivariate analysis, male gender (p=0.011), early virological response (p<0.001), genotype 2/3 (p<0.001), HCV RNA <6x10(5) IU/mL (p=0.005) and adherence to the drug >80% of the planned dose (p<0.001) were associated with SVR. The rate of premature discontinuation was 35.7%. The main reason for withdrawal was intolerance to the drug due to common adverse events or cytopenia (48.2%). Conclusions: Our data suggest that the efficacy of peginterferon and ribavirin therapy in Koreans is better in Koreans than in Caucasians for the treatment of CHC, corroborating previous studies that have shown the superior therapeutic efficacy of this regimen in Asians. (Gut Liver 2012;6:98-106) | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | EDITORIAL OFFICE GUT & LIVER | - |
dc.subject | VIROLOGICAL RESPONSE | - |
dc.subject | COMBINATION THERAPY | - |
dc.subject | (40 KD)/RIBAVIRIN | - |
dc.subject | VIRUS-INFECTION | - |
dc.subject | ASSOCIATION | - |
dc.subject | CIRRHOSIS | - |
dc.subject | IL28B | - |
dc.title | Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yim, Hyung Joon | - |
dc.identifier.doi | 10.5009/gnl.2012.6.1.98 | - |
dc.identifier.scopusid | 2-s2.0-84862910095 | - |
dc.identifier.wosid | 000299367400014 | - |
dc.identifier.bibliographicCitation | GUT AND LIVER, v.6, no.1, pp.98 - 106 | - |
dc.relation.isPartOf | GUT AND LIVER | - |
dc.citation.title | GUT AND LIVER | - |
dc.citation.volume | 6 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 98 | - |
dc.citation.endPage | 106 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001629033 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | VIROLOGICAL RESPONSE | - |
dc.subject.keywordPlus | COMBINATION THERAPY | - |
dc.subject.keywordPlus | (40 KD)/RIBAVIRIN | - |
dc.subject.keywordPlus | VIRUS-INFECTION | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | CIRRHOSIS | - |
dc.subject.keywordPlus | IL28B | - |
dc.subject.keywordAuthor | Chronic hepatitis C | - |
dc.subject.keywordAuthor | Pegylated interferon alpha | - |
dc.subject.keywordAuthor | Ribavirin | - |
dc.subject.keywordAuthor | Korean | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.